Download MendeleyDiscovery of Potent Isoindolinone Inhibitors That Target an Active Conformation of PARP1 Using DNA-Encoded Libraries.
McCarthy, K.A., Marcotte, D.J., Parelkar, S., McKinnon, C.L., Trammell, L.E., Stangeland, E.L., Jetson, R.R.(2024) ChemMedChem : e202400093-e202400093
- PubMed: 38482564
- DOI: https://doi.org/10.1002/cmdc.202400093
- Primary Citation of Related Structures:
8U4W - PubMed Abstract:
Inhibition of poly (ADP-ribose) polymerase-1 (PARP1), a DNA repair enzyme, has proven to be a successful strategy for the treatment of various cancers. With the appropriate selection conditions and protein design, DNA-encoded library (DEL) technology provides a powerful avenue to identify small molecules with the desired mechanism of action towards a target of interest. However, DNA-binding proteins, such as PARP1, can be challenging targets for DEL screening due to non-specific protein-DNA interactions. To overcome this, we designed and screened a PARP1 catalytic domain construct without the autoinhibitory helical domain. This allowed us to interrogate an active, functionally-relevant form of the protein resulting in the discovery of novel isoindolinone PARP1 inhibitors with single-digit nanomolar potency. These inhibitors also demonstrated little to no PARP1-DNA trapping, a property that could be advantageous in the clinic.
Organizational Affiliation:
Valo Health Inc, Discovery Sciences, UNITED STATES.
